Advanced search
Publication Cover
Pharmacogenomics and Personalized Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
127
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Reversal of Chemotherapy Resistance to Cisplatin in NSCLC by miRNA-195-5p via Targeting the FGF2 Gene

Hao Wang1 Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of China;2 Department of Surgical Oncology, Baotou Cancer Hospital, Baotou, People’s Republic of ChinaView further author information
,
Zhi-lin Sui1 Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of ChinaView further author information
,
Xian-xian Wu1 Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of ChinaView further author information
,
Peng Tang1 Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of ChinaView further author information
,
Hong-dian Zhang1 Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of ChinaView further author information
&
Zhen-tao Yu1 Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Tianjin, 300060, People’s Republic of China;3 Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
Pages 497-508 | Published online: 28 Apr 2021

References

  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.21338
  • Jin L, Xu M, Luo XH, Zhu XF. Stephania tetrandra and ginseng-containing chinese herbal formulation NSENL reverses cisplatin resistance in lung cancer xenografts. Am J Chin Med. 2017;45(2):385–401. doi:10.1142/S0192415X17500240
  • Jayaraj R, Kumarasamy C, Sabarimurugan S, Baxi S. Diagnostic and prognostic value of microRNAs for cancers’ strategies and approaches to improve the clinical utility. J Cancer. 2019;10(5):1252–1253. doi:10.7150/jca.28581
  • Yu W, Liang X, Li X, et al. MicroRNA-195: a review of its role in cancers. Onco Targets Ther. 2018;11:7109. doi:10.2147/OTT.S183600
  • Hu M, Hu Y, He J, Li B. Prognostic value of basic fibroblast growth factor (bFGF) in lung cancer: a systematic review with meta-analysis. PLoS One. 2016;11(1):e0147374. doi:10.1371/journal.pone.0147374
  • Arrieta O, Lazcano E. Cáncer de pulmón. El peso de la enfermedad y avances en el diagnóstico y tratamiento [Lung cancer. Epidemiology, diagnosis and treatment]. Salud Publica Mex. 2019;61(3):217–218. Spanish. doi:10.21149/10660
  • Fang L, Niyanhan J, Wenjie L, et al. Research progress on the mechanism of cancer drug resistance. Anti-Tumor Pharm. 2018;8(3):307–312.
  • Jiang T, Dong P, Li L, et al. MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells. Oncol Rep. 2017;38(1):151–158. doi:10.3892/or.2017.5659
  • Song LY, Ma YT, Wu CF, Wang CJ, Fang WJ, Liu SK. MicroRNA-195 activates hepatic stellate cells in vitro by targeting Smad7. Biomed Res Int. 2017;2017. doi:10.1155/2017/1945631
  • Zhang X, Ji R, Liao X, et al. MicroRNA-195 regulates metabolism in failing myocardium via alterations in sirtuin 3 expression and mitochondrial protein acetylation. Circulation. 2018;137(19):2052–2067. doi:10.1161/CIRCULATIONAHA.117.030486
  • Zhang W, Wang Y, Zhu Z, et al. Propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195. Int J Biol Macromol. 2018;120:975–984. doi:10.1016/j.ijbiomac.2018.08.173
  • Zuo W, Zhang W, Xu F, et al. Long non-coding RNA LINC00485 acts as a microRNA-195 sponge to regulate the chemotherapy sensitivity of lung adenocarcinoma cells to cisplatin by regulating CHEK1. Cancer Cell Int. 2019;19(1):1–16. doi:10.1186/s12935-019-0934-7
  • Li Y, Guo XB, Wang JS, Wang HC, Li LP. Function of fibroblast growth factor 2 in gastric cancer occurrence and prognosis. Mol Med Rep. 2020;21(2):575–582. doi:10.3892/mmr.2019.10850
  • Teng Y, Guo B, Mu X, Liu S. KIF26B promotes cell proliferation and migration through the FGF2/ERK signaling pathway in breast cancer. Biomed Pharmacother. 2018;108:766–773. doi:10.1016/j.biopha.2018.09.036
  • Hu N, Kadota M, Liu H, et al. Genomic landscape of somatic alterations in esophageal squamous cell carcinoma and gastric cancer. Cancer Res. 2016;76(7):1714–1723. doi:10.1158/0008-5472.CAN-15-0338
  • Huang X, Wang L, Liu W, Li F. MicroRNA-497-5p inhibits proliferation and invasion of non-small cell lung cancer by regulating FGF2. Oncol Lett. 2019;17(3):3425–3431. doi:10.3892/ol.2019.9954
  • Wang J, Shu H, Guo S. MiR-646 suppresses proliferation and metastasis of non-small cell lung cancer by repressing FGF2 and CCND2. Cancer Med. 2020;9(12):4360–4370. doi:10.1002/cam4.3062
  • Li F, Zhu T, Yue Y, Zhu X, Wang J, Liang L. Preliminary mechanisms of regulating PD-L1 expression in non-small cell lung cancer during the EMT process. Oncol Rep. 2018;40(2):775–782. doi:10.3892/or.2018.6474
  • Schelch K, Wagner C, Hager S, et al. FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. Carcinogenesis. 2018;39(4):534–545. doi:10.1093/carcin/bgy018
  • Chen X, Zhao H, Chen C, et al. The HPA/SDC1 axis promotes invasion and metastasis of pancreatic cancer cells by activating EMT via FGF2 upregulation. Oncol Lett. 2020;19(1):211–220. doi:10.3892/ol.2019.11121
  • Kurimoto R, Iwasawa S, Ebata T, et al. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol. 2016;48(5):1825–1836. doi:10.3892/ijo.2016.3419
  • Lou Y, Diao L, Cuentas ER, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 2016;22(14):3630–3642. doi:10.1158/1078-0432.CCR-15-1434

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.